类有机物
免疫系统
医学
计算生物学
精确肿瘤学
精密医学
生物
肿瘤科
免疫学
病理
神经科学
作者
Vinh Dao,Kanako Yuki,Yuan–Hung Lo,Michitaka Nakano,Calvin J. Kuo
标识
DOI:10.1016/j.trecan.2022.06.001
摘要
Cancer immunotherapies, particularly immune checkpoint inhibitors, are rapidly becoming standard-of-care for many cancers. The ascendance of immune checkpoint inhibitor treatment and limitations in the accurate prediction of clinical response thereof have provided significant impetus to develop preclinical models that can guide therapeutic intervention. Traditional organoid culture methods that exclusively grow tumor epithelium as patient-derived organoids are under investigation as a personalized platform for drug discovery and for predicting clinical efficacy of chemotherapies and targeted agents. Recently, the patient-derived tumor organoid platform has evolved to contain more complex stromal and immune compartments needed to assess immunotherapeutic efficacy. We review the different methodologies for developing a more holistic patient-derived tumor organoid platform and for modeling the native immune tumor microenvironment.
科研通智能强力驱动
Strongly Powered by AbleSci AI